• Anaphylaxis

Symjepi Generic Name & Formulations

General Description

Epinephrine 0.15mg, 0.3mg; per prefilled syringe; soln for IM or SC inj; contains sulfites.

Pharmacological Class


How Supplied

Packs—1, 2


Generic Availability


Symjepi Indications


Emergency treatment of allergic reactions (Type 1) including anaphylaxis.

Symjepi Dosage and Administration

Adults and Children

Give by IM or SC inj into the anterolateral aspect of the thigh only. 15–30kg: 0.15mg. ≥30kg: 0.3mg. May repeat another dose if needed.

Symjepi Contraindications

Not Applicable

Symjepi Boxed Warnings

Not Applicable

Symjepi Warnings/Precautions


The presence of sulfite in this product should not deter use. Cardiovascular disease. Hypertension. Hyperthyroidism. Diabetes. Parkinson’s disease. Injection-related complications: do not inject intravenously or into buttock (risk of Clostridium infection), digits, hands, or feet; hold leg firmly and limit movement in children prior to and during injection. Advise patient to seek medical help immediately. Train patient in use of device. Elderly. Pregnancy. Nursing mothers.

Symjepi Pharmacokinetics

See Literature

Symjepi Interactions


May be potentiated by MAOIs, tricyclic antidepressants, levothyroxine, antihistamines (eg, chlorpheniramine, tripelennamine, diphenhydramine). May be antagonized by β-blockers (eg, propranolol), α-blockers (eg, phentolamine), ergot alkaloids. Arrhythmias possible with cardiac glycosides, diuretics, or anti-arrhythmics.

Symjepi Adverse Reactions

Adverse Reactions

Anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea, vomiting, headache, respiratory difficulties; arrhythmias, angina pectoris; rare: serious skin and soft tissue infections at inj site, stress cardiomyopathy.

Symjepi Clinical Trials

See Literature

Symjepi Note

Not Applicable

Symjepi Patient Counseling

See Literature